Insider Selling: United Therapeutics (NASDAQ:UTHR) Director Sells 1,000 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) Director Christopher Causey sold 1,000 shares of the stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $520.00, for a total transaction of $520,000.00. Following the completion of the transaction, the director directly owned 4,190 shares of the company’s stock, valued at $2,178,800. This trade represents a 19.27% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Christopher Causey also recently made the following trade(s):

• On Tuesday, January 6th, Christopher Causey sold 1,000 shares of United Therapeutics stock. The shares were sold at an average price of $510.00, for a total transaction of $510,000.00.
• On Friday, January 2nd, Christopher Causey sold 1,000 shares of United Therapeutics stock. The stock was sold at an average price of $500.01, for a total transaction of $500,010.00.

United Therapeutics Trading Up 13.0%

NASDAQ:UTHR traded up $61.67 on Wednesday, hitting $535.10. The company had a trading volume of 1,042,334 shares, compared to its average volume of 347,023. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $537.19. The stock has a market capitalization of $23.04 billion, a price-to-earnings ratio of 20.28, a PEG ratio of 2.53 and a beta of 0.85. The firm has a 50 day moving average of $484.23 and a two-hundred day moving average of $443.45.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.78 by $0.92. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The company had revenue of $790.20 million during the quarter, compared to the consensus estimate of $814.80 million. During the same period in the prior year, the business earned $6.19 earnings per share. The company’s revenue for the quarter was up 7.4% compared to the same quarter last year. As a group, equities analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current year.

More United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Q4 EPS beat and improving margins — UTHR reported $7.70 EPS vs. the $6.78 consensus and showed a healthy net margin (~40.7%), which supports near-term earnings credibility. United Therapeutics (UTHR) Surpasses Q4 Earnings Estimates
• Positive Sentiment: Record full-year revenue — FY2025 revenue rose to $3.18B (up ~11% YoY), reinforcing longer-term growth trajectory beyond the quarter. United Therapeutics Corporation Reports Fourth Quarter and Full Year 2025 Financial Results
• Neutral Sentiment: Unusual options and high volume — Traders bought an elevated number of call contracts (4,930 calls, ~241% above average) and overall volume spiked, which can magnify intraday moves but is non-directional on fundamentals.
• Neutral Sentiment: Analyst stance mixed — Morgan Stanley reiterated a Hold with a $447 price target, signaling cautious near-term sentiment despite solid results. Balanced Hold on United Therapeutics Amid Near-Term Pressure and Key Late-Stage Pipeline Readouts
• Negative Sentiment: Revenue miss pressured the stock — Quarterly revenue of $790.2M came in below the ~$814.8M consensus, which was cited as the main reason for an early sell-off. United Therapeutics stock falls nearly 5% on revenue miss despite earnings beat
• Negative Sentiment: Sizable insider selling — COO Michael Benkowitz sold sizable blocks (multiple recent transactions totaling tens of thousands of shares), which can be interpreted negatively by some investors. United Therapeutics (NASDAQ:UTHR) COO Michael Benkowitz Sells 14,440 Shares

Analyst Ratings Changes

Several analysts have recently weighed in on UTHR shares. Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. Royal Bank Of Canada upped their price target on shares of United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a research report on Thursday, October 30th. HC Wainwright lifted their price target on shares of United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a report on Thursday, October 30th. UBS Group reissued a “buy” rating on shares of United Therapeutics in a research note on Tuesday, February 17th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $575.00 target price on shares of United Therapeutics in a research report on Wednesday, November 19th. Eight equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $509.50.

Institutional Investors Weigh In On United Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Torren Management LLC purchased a new stake in shares of United Therapeutics in the fourth quarter worth approximately $26,000. Activest Wealth Management boosted its holdings in shares of United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after buying an additional 56 shares during the last quarter. WealthCollab LLC grew its position in shares of United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 38 shares during the period. Rakuten Securities Inc. grew its holdings in United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 46 shares during the period. Finally, Entrust Financial LLC bought a new position in shares of United Therapeutics during the 4th quarter worth $31,000. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.